To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8 + T cells in patients with pancreatic ductal adenocarcinoma (PDAC), ...

Immune checkpoint inhibitors, popularized by Allison and Honjo’s Nobel Prize, were one of the first cancer immunotherapies that gained FDA approval. In the 1990s, Allison and Honjo identified the ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, multiple sclerosis, shows a new study in mice. In these autoimmune diseases ...

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...